Amgen shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint, with investors assessing the impact on AMGN's olpasiran phase III study. Also, BMO Capital downgraded its rating on the stock from Outperform to Market Perform and maintained its $450 price target.
Amgen shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint, with investors assessing the impact on AMGN's olpasiran phase III study. Also, BMO Capital downgraded its rating on the stock from Outperform to Market Perform and maintained its $450 price target.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day